On Sunday, October 5, 2014, an innovative molecular diagnostics technology from MetaStat, Inc. (MTST-OTC) was spotlighted in a WABC-TV news special.
Posted by Laura Swartz
October 8, 2014 at 2:12 PM
On Sunday, October 5, 2014, an innovative molecular diagnostics technology from MetaStat, Inc. (MTST-OTC) was spotlighted in a WABC-TV news special.
Topics: MetaStat
Posted by Laura Swartz
April 23, 2014 at 4:59 PM
This afternoon, we released a new Executive Informational Overview (EIO) on MetaStat, Inc. (MTST-OTC). This comprehensive, 68-page document updates an earlier EIO published on MetaStat in January 2013. The Company has achieved several significant milestones over the past year and a half, which are each detailed in the new EIO along with current product development and market descriptions for MetaStat’s diagnostic and therapeutic programs.
Company IntroductionMetaStat is a life sciences company commercializing a new approach to reliably determine a patient’s individual risk of developing systemic metastatic cancer, and then to help reduce this risk through active intervention of the metastatic process. The Company’s technology is based on a proprietary knowledge of the mechanisms that govern “metastasis” (the spread of cancer away from its primary site in the body).
The technology centers on the role of the Mena protein in tumors, and has over 15 years of study from major medical institutions including MIT, the Albert Einstein College of Medicine of Yeshiva University, Cornell University, and the IFO-Regina Elena Cancer Institute. Recent clinical studies validating MetaStat’s product candidates have also been performed by the Yale University School of Medicine, the University of Toronto, and others.
MetaStat is initially advancing two diagnostic platforms targeting breast, prostate, lung, and colorectal cancers, which could enter the market as early as 2015, as well as a therapeutic program.
The Company believes that its function-based diagnostics can inform better treatment decisions by identifying patients with a high risk of systemic metastasis who need aggressive therapy and sparing patients with a low risk of metastasis from painful and costly therapies. The National Institutes of Health (NIH) recently concluded that a primary goal in cancer research should be to accurately define patient risk categories with the goal of being able to administer the level of treatment needed for a successful outcome.
Milestones and Report Topics
Click here to download and read the full Executive Informational Overview, which includes a discussion of the recent milestones listed below.
Topics: MetaStat
Posted by Colleen Koski
August 15, 2013 at 1:25 PM
Last week, Jeff Kraws sat down with Rhonda Schaffler at Reuters to discuss opportunities and trends in the biotech space. Mr. Kraws is a veteran Wall Street sell-side analyst with more than 20 years of experience and is also cofounder and CEO of Crystal Research Associates. If you enjoyed the short clip of this interview released earlier this week, the full segment (available below) goes into more detail on individual biotech stocks and the events every investor should be watching out for.
Topics: AtheroNova, Crystal Research Associates, Unilife Corp., biotech, MetaStat, Reuters
Posted by Colleen Koski
April 19, 2013 at 9:13 AM
Yesterday, Crystal Research Associates published a 12-page Quarterly Update on MetaStat, Inc., a life sciences company developing next-generation diagnostic and therapeutic products for metastatic cancer. MetaStat is currently focused on three key initiatives within its pipeline: two diagnostic platforms (MetaSite™ Breast and MenaCalc™) as well as one therapeutic program (MenaBloc™). These candidates are overviewed on pages 5-8 of MetaStat's Quarterly Update.
Key Developments
Topics: MetaStat
Posted by Laura Swartz
February 13, 2013 at 3:14 PM
This morning, Crystal Research's CEO Jeff Kraws was invited to participate in a roundtable discussion to analyze how investors should be reacting to President Obama's State of the Union address. The segment was hosted by Thomson Reuters' Rhonda Schaffler and also featured David Joy, Chief Market Strategist of Ameriprise Financial, and Craig Irwin, Senior Vice President at Wedbush Securities.
Topics: Bridgelux, Crystal Research Associates, nanotechnology, green infrastructure, Unilife Corp., MetaStat
Posted by Colleen Koski
January 9, 2013 at 12:23 PM
Topics: MetaStat
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.
CONTACT INFORMATION
Phone: (212) 851-6685